Surgical Treatment and Prognosis of Angiosarcoma of the Scalp: A Retrospective Analysis of 14 Patients in a Single Institution

Jun Ho Choi, Kyung Chan Ahn, Hak Chang, Kyung Won Minn, Ung Sik Jin, and Byung Jun Kim

Department of Plastic and Reconstructive Surgery, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Republic of Korea

Correspondence should be addressed to Byung Jun Kim; bjkim79@gmail.com

Received 11 September 2015; Revised 9 November 2015; Accepted 15 November 2015

Objective. We describe specific surgical methods for angiosarcoma regarding extent of resection and reconstructive options and assess their effect on patients’ prognosis.

Patients and Methods. We retrospectively examined 14 patients undergoing treatment for angiosarcoma of the scalp at our institute between January 2000 and June 2015. Surgical treatment comprised wide excision of the tumor and reconstruction using a free flap with skin graft. Kaplan-Meier survival analysis was used to assess the survival parameters. Univariate and multivariate analyses were performed to evaluate the association between risk factors and outcome parameters.

Results. Mean patient age at diagnosis was 69 years, and the mean follow-up period was 17 months. The overall 5- and 2-year survival rates were 15% and 75%, respectively, whereas the 5- and 2-year disease-free survival rates were 7.7% and 38.7%, respectively. The mean survival duration was 32 months. Metastatic tumor dissemination to the lung or brain was closely associated with the major cause of death. Only a deep excision margin was significantly related to the recurrence rate.

Conclusions. Cases of angiosarcoma had a poor prognosis despite the aggressive treatments. Sufficient resection margins are essential for controlling local recurrence. The effect of multidisciplinary approaches needs to be explored.

1. Introduction

Angiosarcoma (AS) is rare vascular neoplasm affecting the endothelial cells of blood vessel. Cutaneous AS usually develops in the face or scalp [1, 2]. This tumor predominantly develops in elderly people and more frequently affects men than women [2–4]. AS accounts for less than 2% of all cases of soft-tissue sarcoma and less than 1% of cases of head and neck cancer [5–7]. The etiology of AS has not been fully understood, but several reports have shown some positive association with chronic lymphedema [8] or prior irradiation [9, 10]. It is a highly aggressive malignant tumor with a high rate of locoregional recurrence and tends to metastasize at an earlier stage. Although various active treatment options have been adopted, the associated prognosis remains poor. Many studies have indicated that the 5-year survival rate of AS ranges between 10% and 50% [4, 7, 11–13]. No common consensus has been reached regarding the optimal treatment [6]. However, a multimodality approach of wide excision and radiotherapy is broadly accepted as the standard treatment [2, 6, 14]. As concrete surgical strategies have still not been established, in the present report, we describe surgical methods for AS in terms of the extent of resection and reconstructive options and assess their effect on patient prognosis.

2. Materials and Methods

2.1. Study Design and Patients. The subjects of the present study are patients with AS of the scalp, who were treated at our institute between January 2000 and June 2015, and their medical records were retrospectively reviewed. All the procedures in the present study were approved by our institutional review board (IRB number: 1508-088-695). Patients in the study were primarily diagnosed with AS, and there was no prior history of radiotherapy. Patients with AS located at any other site except the scalp were excluded from the study. The reason for such exclusion was that the scalp has a unique anatomy which significantly affects the surgical decisions.
Patients with other malignancies such as hemangiopericytoma, Kaposi's sarcoma, and malignant fibrous histiocytoma were also excluded. The risk factors of demographic data of patients, horizontal and vertical dimensions of resection, and adjuvant treatments were explored, and their effects on the recurrence rates, metastasis, and patient survival were analyzed.

2.2. Treatment and Evaluations. Preoperative evaluation comprised pathologic confirmation of the skin biopsy specimens or reconfirmation using histologic slides at other centers, magnetic resonance imaging (MRI) of the brain, chest radiography, computed tomography (CT) of the neck, positron emission tomography (PET), and bone scan of the whole body. They all showed no evidence of metastasis to distant organs. Scalp hair was removed preoperatively, and the lesion was reevaluated. For skin margins without definitive presentation, mapping biopsies were performed in outpatient clinic to determine the extent of resection. In the operating theater, the boundary of the primary lesion was reconfirmed, and the lateral resection margins—free from the tumor—were determined. Thereafter, a wide excision was performed, while ensuring sufficient safety margins, to obtain clear lateral and deep resection margins according to the initial surgical plan (Table 1). After removing the primary lesion, an intraoperative frozen biopsy was performed to establish clear surgical margins (Figure 1). The resultant defect was reconstructed by the free latissimus dorsi (LD) muscle flap. After successful microanastomosis between the vascular pedicles of the flap (thoracodorsal (TD) artery and vein) and the recipient vessels (superficial temporal (ST) artery and vein), the raw surface was covered with the muscle flap and a split-thickness skin graft (Figure 1). Cervical lymph node dissection was performed only in patients who were suspected to have regional lymph node metastasis, as confirmed by preoperative imaging studies. Outpatient clinic-based follow-ups were performed postoperatively, every 3 months during the first year and then every 6 months over the next 1 year. During each visit, brain MRI and chest radiography were performed in each patient for determining recurrence or metastasis. At 1 month postoperatively, complete wound healing was verified, and then radiation therapy was initiated selectively based on the protocol of our institution.

2.3. Statistical Analysis. The Kaplan-Meier method was used to determine overall survival, median survival, and disease-free survival rates. To evaluate the association between risk factors and outcome parameters, the Cox regression test was chosen for univariate and multivariate analyses. Statistical analysis was performed using version 9.3 of the SAS program (SAS Institute Inc., Cary, North Carolina, USA). A P value < 0.05 was considered statistically significant.

3. Results
We retrospectively reviewed the records of a total of 14 patients (13 males and 1 female). The patients’ demographic characteristics are presented in Table 1. All patients were Korean, and the mean age at the diagnosis was 69 (range: 52–81) years, whereas the mean follow-up period was 17 (range: 8–87) months. At the time of the initial diagnosis, 9 patients had high blood pressure requiring antihypertensive medication, 1 patient had chronic obstructive pulmonary disease, 1 patient had chronic kidney disease, and 1 patient had a history of a cerebrovascular event. With regard to the postoperative adjuvant treatment, 3 patients received radiotherapy alone, 3 patients received chemotherapy alone, and 5 patients received both radiotherapy and chemotherapy. No revision surgery due to vascular compromise of the flap was required in any of these cases. Moreover, postoperative complications such as hematoma, wound infection, or flap failure were not observed. After radiation therapy was administered, partial loss of the skin graft was observed in some cases. However, the degree of loss was not significant, and wound healing was completed by secondary intention. In 1 patient, an additional split-thickness skin graft was applied to cover the raw surface in the operating room. The overall 5- and 2-year survival rates were 15% and 75%, respectively, whereas the 5- and 2-year disease-free survival rates were 7.7% and 38.7%, respectively. The mean survival duration was 32 months (Figures 2 and 3).
Table 1: Overall information of 14 patients with angiosarcoma of the scalp.

| Patient number | Gender | Age at Dx (years) | Tumor size at Dx (cm) | Resection margin (cm) | Deep margin | Reconstruction methods | Biopsy results | Adjuvant therapy | Profile of radiotherapy | Local recurrence (months) | Metastasis (months) | Meta area | Death (months) |
|----------------|--------|-------------------|----------------------|----------------------|-------------|-----------------------|---------------|------------------|----------------------|------------------------|------------------------|-----------|--------------|
| 1              | M      | 52                | 3 x 2                | 1                    | G           | FF, SG                | MN            | C                | Null                 | 5                      | 69                     | Lung      | 85           |
| 2              | M      | 70                | 8.5 x 5              | 2                    | B           | FF, SG                | MN            | RT, C            | 63 Gy                | 15                     | 21                     | LRR       | 30           |
| 3              | M      | 61                | 4 x 3                | 3                    | P           | FF, SG                | MN            | C                | Null                 | 10                     | 12                     | Brain     | 23           |
| 4              | F      | 64                | 9 x 5.5              | 2                    | P           | FF, SG                | MN            | RT, C            | NR                   | 7                      | FL                     | LRR       | FL           |
| 5              | M      | 76                | 5 x 5                | 5                    | B           | FF, SG                | MN            | null             | Null                 | NE                     | 45                     | Lung      | 48           |
| 6              | M      | 71                | 5 x 4                | 5                    | P           | FF, SG                | MN            | RT, C            | 61 Gy                | 9                      | 13                     | Bone      | NE           |
| 7              | M      | 70                | 4 x 4                | 5                    | B           | FF, SG                | MN            | null             | Null                 | 17                     | 36                     | Brain     | 37           |
| 8              | M      | 75                | 9.5 x 7              | NR                   | B           | FF, SG                | MP            | C                | Null                 | 11                     | FL                     | Null      | FL           |
| 9              | M      | 64                | 3 x 2.5              | 3                    | B           | FF, SG                | MN            | RT, C            | 30 Gy                | 13                     | 20                     | Lung      | 32           |
| 10             | M      | 81                | 3 x 3                | 1                    | G           | LF                    | MN            | null             | Null                 | 7                      | 9                      | Lung      | 13           |
| 11             | M      | 58                | 3 x 3                | 2                    | P           | FF, SG                | MN            | RT, C            | 61 Gy                | 8                      | 10                     | Lung      | NE           |
| 12             | M      | 75                | 13 x 8               | 3                    | P           | FF, SG                | MN            | RT, C            | 50 Gy                | 11                     | NE                     | Null      | NE           |
| 13             | M      | 81                | 11.5 x 6.0           | 3                    | B           | FF, SG                | MN            | RT, C            | 42 Gy                | 5                      | NE                     | Null      | NE           |
| 14             | M      | 68                | 6 x 6                | 3                    | B           | FF, SG                | MN            | RT               | 50 Gy                | NE                     | NE                     | Null      | NE           |

Dx: diagnosis; cm: centimeters; Meta area: area of metastasis; M: male; F: female; NR: not recorded; G: galea; P: periosteum; B: bone; FF: free flap; LF: local flap; SG: skin graft; MP: margin positive; MN: margin negative; RT: radiotherapy; C: chemotherapy; Gy: grays; NE: no event; FL: follow-up loss; LRR: locoregional recurrence.
Metastatic tumor dissemination to the lung or brain was associated with a major cause of death. Among the 14 patients, 7 patients were observed until the time of death. The major causes of death were the following: 4 cases of serious pulmonary complications as a result of lung metastasis and 2 cases of intracranial hemorrhage as a result of a metastatic brain tumor. The common chief complaints when visiting the emergency room were sudden onset dyspnea or hemoptysis in patients who had pulmonary metastasis and sudden onset altered mentality, limb weakness, or dysarthria in patients who had brain metastasis. None of the risk factors, except for a deep surgical margin for excision, were significantly associated with the rates of recurrence, metastasis, and patient survival. Although a deep excision margin was the only factor significantly associated with the rate of recurrence, it was not significantly associated with the rate of metastasis or the patient survival. The hazard ratio for local recurrence was increased to 24.15 (95% confidence interval: 2.12–275.24) when the periosteum was preserved, as compared to when the periosteum and bone were resected ($P < 0.05$) (Figure 4). Of the 14 patients, 1 experienced postoperative depression and was therefore referred to a psychiatrist.

4. Discussion

The poor prognosis of AS is reportedly associated with various factors. First, the definite diagnosis in these cases is often delayed or incorrect; therefore, the disease is already at an advanced stage during the initial presentation. AS usually has an insidious growth pattern, and the clinical features
Figure 5: Various preoperative clinical features of angiosarcoma of the scalp: ulcerative type (a), bruise-like type (b), and nodular type (c).

may vary [15, 16] (Figure 5). Benign diseases such as hemangioma or vascular malformation, pigmented skin lesions, seborrheic dermatitis or seborrheic keratosis, nodular or ulcerated skin lesions, and inflammatory skin conditions may make differential diagnosis difficult [4]. Moreover, malignant neoplasms, such as malignant melanoma, can mimic the presentation of AS [1]. These factors may often lead to the lack of recognition by patients as well as the lack of perception by physicians. Hence, a high grade of suspicion and adequate skin biopsy in the earlier stage of the disease are necessary for accurate diagnosis. Second, vascular origin of AS may be associated with poor prognosis, and AS has a high incidence of hematogenous spread [2]. The most common distant metastatic site for AS is the lung [4, 17], although the brain is also prone to the dissemination of tumor cells [17]. Third, AS tends to develop as multiple lesions, which makes it difficult to define a clear boundary for the tumor [1]. In the cases of satellite lesions, the residual tumor may be occult, even after wide excision. Fourth, cutaneous AS is a very rare disease even among malignant cancers, and the accumulated clinical experience on AS remains insufficient. Consequently, there is no clear consensus regarding the treatment protocol.

The anatomy of the scalp is unique and affects the clinical course of AS [16]. There is considerable arterial blood supply to the scalp [18]; in particular, diverse branches originating from both internal and external carotid arterial systems anastomose in the scalp. Compared to such horizontal arterial patterns of arterial supply, venous drainage displays both horizontal and vertical patterns. The horizontal drainage of the superficial vein travels along the arterial pathway. However, there are also special vertical venous channels that are directly linked with the intracranial space. These are termed emissary veins; due to the direct interconnection of these veins, the tumor can easily spread into the brain parenchyma. This anatomic characteristic may explain higher occurrences of brain metastasis; in fact, 2 of 7 patients in the present study died due to intracranial hemorrhage after brain metastasis. Unlike the face, only a few important structures need to be preserved in the scalp, in terms of functional or aesthetic aspects. Hence, surgeons can acquire a more sufficient resection margin, free from the tumor, when performing wide excision of AS in the scalp.

After the radical resection of AS, the wide defect was reconstructed using free LD muscle flap and a split-thickness skin graft. Risk factor analysis indicated that a deep margin for excision was significantly associated with the rate of recurrence. The periosteum should be stripped off to reduce the risk of local recurrence. A wide tissue defect without any periosteum is recommended to be reconstructed using free flap transfer, and the LD muscle flap may be a good candidate regarding its size. In addition, TD vascular pedicles have compatible calibers and sufficient length as compared to ST recipient vessels. If a muscle flap is located under the skin graft, more rapid secondary healing is expected. The aesthetic outcome after reconstruction with the combination of free muscle flap and skin graft was acceptable, with considering scalp contour and skin color matching. We did not observe any complications related to the flap operation, such as hematoma under the flap, infection, or loss of the flap.

The 5-year survival rate in the present study was 15%, which is consistent with the values reported in the literature (10–50%) (Table 2) [4, 7, 11–13]. Complete excision is considered to be important for overall survival in patients with AS. However, only a few studies have described the specific surgical protocol and its relationship with prognosis. The extent of the lateral safety margin was not significantly correlated with outcome parameters, due to a small sample size. A larger number of patients in a future study may indicate a statistical association between the extent of the lateral safety margin and the clinical outcomes. The depth of excision should reach the periosteum, in order to prevent tumor recurrence.

The current primary treatment of AS involves complete excision of the tumor and adjuvant radiotherapy; however, the prognosis of AS remains obscure. We assume the mapping biopsy helps in determining surgical margin in advance, and the effectiveness of such procedure has been affirmed through previous studies in AS and extramammary Paget's
Table 2: A review of literatures.

| Authors                  | Year | N  | M (F) | Age at Dx | Race | Location of tumor | Treatment | Surgical method | Mean f/u period (months) | 5-year OSR (%) | 5-year DFSR (%) | 2-year OSR (%) | 2-year DFSR (%) | MS (months) |
|--------------------------|------|----|-------|----------|------|-------------------|-----------|----------------|------------------------|----------------|----------------|----------------|----------------|-----------|
| Hodgkinson et al. [12]   | 1979 | 13 | 7 (6) | 66       | NR   | Head and neck    | S (5), S + RT (5), RT (3) | NR            | 13 (1-96) | NR         | NR          | NR          | NR         |
| Holden et al. [4]        | 1987 | 72 | 44 (28)| 74       | C    | Scalp and face   | S + RT (3), RT (69)        | NR            | 12 (12-144) | NR         | 12          | NR          | 15         |
| Mark et al. [7]          | 1996 | 28 | 21 (7) | 61-83    | NR   | Head and neck    | S (12), S + CT (3), S + RT ± CT (6), RT ± CT (7) | NR            | 32 (3-159) | NR         | 26          | NR          | NR         |
| Lydiatt et al. [6]       | 1994 | 18 | 13 (5) | 67       | C (17)| Head and neck    | S (6), S + RT (2), S + CT (1), CT (19)           | NR            | NR         | 33          | 20          | NR         |
| Morrison et al. [19]     | 1995 | 14 | 8 (6)  | 66       | C    | Scalp and face   | S + RT (6), RT (3), S + RT ± CT (11)              | STSG          | NR         | 29          | NR          | NR         | 22         |
| Pawlik et al. [11]       | 2003 | 29 | 18 (11)| 71 (33-90)| C (28), A (1) | Scalp | S + RT (28), RT (1) | WE, LF (2), and STSG (26) | 18.3 (3.2–106) | 12 | NR          | NR          | NR          | 28.4        |
| Ohguri et al. [20]       | 2005 | 20 | 11 (9) | 71 (49-91)| A (J) | Scalp | RT + IT | NR         | 29.5 (5-120) | NR         | NR          | NR          | NR         |
| Buschmann et al. [16]    | 2008 | 19 | 14 (5) | 77 (59-86)| NR   | Scalp | S + RT ± CT | Oc + STSG | NR         | NR          | NR          | NR         |
| Köhler et al. [21]       | 2008 | 23 | 11 (12)| 63 (12-75)| C (19), AA (3), and A (1) | Head and neck | S + RT (19), S + CT (2), S + RT + CT (2) | WE (2 cm) | 19.7 (5-108) | 21.7 | NR          | NR          | NR         |
| Lim et al. [22]          | 2010 | 9  | 5 (4)  | 71 (64-82)| A (K) | Scalp | S ± RT (8) | WE (5 cm) + Oc + LD + STSG + Pr + Nd | 24 | NR         | NR          | NR         | 100        | 15         |
| Ogawa et al. [23]        | 2012 | 48 | 29 (19)| 77 (58-94)| A (J) | Scalp and face | S + RT ± CT ± IT (17), S + CT + IT (2), RT ± CT ± IT (20), RT (5), and IT (4) | WE (3-5 cm) | 13.7 (2.5–105.9) | NR       | 22.1 | NR          | 13.4        |
| Dettenborn et al. [24]   | 2014 | 80 | 50 (30)| 71 (SD 14.4)| NR   | Head and neck    | S (32), S + RT (38), S + CT (4), and S + RT + CT (6) | NR            | 55.3 (SD 74.4) | 54 | NR         | 71          | NR         | 64.0 (CI 48.4–75.6) |
| Mullins and Hackman [5]  | 2015 | 6  | 5 (1)  | 66 (52-83)| C (4), AA (2) | Head and neck | S (1), S + RT (2), S + RT + CT (1), and C (2) | NR | 42 | NR         | 20          | 36.7 (5-76) |
| Patel et al. [14]        | 2015 | 55 | 39 (16)| NR       | NR   | Scalp and face   | S ± RT ± CT (39) | NR | 25.2 (4.7–2271) | 38 | 16 | NR          | 25.2        |
| Our study                | 2015 | 14 | 13 (1) | 69 (52-81)| A (K) | Scalp | S (3), S + RT (3), S + CT (3), and S + RT + CT (5) | WE (1-5 cm) | 17 (8-87) | 15         | 77          | 75         | 38.7 (CI 27.0–37.0) |

Year: year of publication; N: number of patients; M: number of male patients; F: number of female patients; Dx: diagnosis; f/u: follow-up; OSR: overall survival rate; DFSR: disease-free survival rate; MS: median survival; SD: standard deviation; NR: not recorded; C: Caucasian; AA: African American; A: Asian; K: Korean; J: Japanese; S: surgery; RT: radiation; CT: chemotherapy; IT: immunotherapy; + and: ± and/or; STSG: split-thickness skin graft; WE: wide excision; LF: local flap; LD: reconstruction using a free latissimus dorsi muscle flap; Oc: outer corticotomy of the calvarium; Pr: ipsilateral parotidectomy; Nd: ipsilateral neck dissection; cm: resection margin in centimeters; CI: 95% confidence interval.
disease [25, 26]. This method facilitates the detection of occult satellite lesions, and it provides indications of the more extensive resection. Aggressive excision of the tumor of the scalp may be more beneficial for patient survival. Gu dewer et al. presented a case of whole scalp reconstruction with a free muscle flap and skin graft after AS resection, with a good postoperative result [1]; the aesthetic results were also satisfactory in that case. According to Lim et al. [22], radical resection with a sufficient safety margin (5 cm) may provide survival advantage. Up-to-date nonsurgical treatment modalities such as immunotherapy or gene therapy may be promising [5, 15, 20]. There are still ongoing debates about the application of chemotherapy in the standard AS treatment. Based on the current updates of literatures, chemotherapy is more recommended in case of recurring AS for the palliative purpose [2, 27–30]. We used chemotherapy ancillary to surgical resections and radiotherapy. Further research and clinical experience are necessary in order to apply new therapeutic modalities. We suggest multidisciplinary approaches to AS patient with active discussions and cooperation among physicians in different fields for maximizing the effect of treatments. For example, our institution has a sarcoma center in the cancer hospital. Medical collaborations were made among departments of plastic and reconstructive surgery, dermatology, medical oncology, radiation oncology, and neurosurgery, and feedback was exchanged before and after the surgery.

The current study had some limitations, including the retrospective study design and small sample size. Moreover, no control group was used for comparison. Hence, a future study with a larger sample size may provide more significant information.

5. Conclusions

AS is a rare and highly aggressive malignant tumor with a poor prognosis. We observed that only a deep margin for excision was significantly related to the rate of recurrence. Hence, ensuring the presence of a sufficient deep margin as well as an adequate lateral margin is essential during wide excision of AS. Further study is also needed to develop new treatments for AS, such as immunotherapy or gene therapy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] E. Gu dewer, E. Hölzle, and L. Li, “Widespread cutaneous angiosarcoma of the scalp: diagnosis and soft tissue reconstruction with a combined double-muscle-free flap and split-thickness-skin graft,” Oral and Maxillofacial Surgery, vol. 13, no. 2, pp. 95–98, 2009.

[2] W. M. Mendenhall, C. M. Mendenhall, J. W. Werning, J. D. Reith, and N. P. Mendenhall, “Cutaneous angiosarcoma,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 29, no. 5, pp. 524–528, 2006.

[3] R. Sasaki, T. Soejima, K. Kishi et al., “Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome,” International Journal of Radiation Oncology Biology Physics, vol. 52, no. 4, pp. 1032–1040, 2002.

[4] C. A. Holden, M. F. Spittle, and E. W. Jones, “Angiosarcoma of the face and scalp, prognosis and treatment,” Cancer, vol. 59, no. 5, pp. 1046–1057, 1987.

[5] B. Mullins and T. Hackman, “Angiosarcoma of the head and neck,” International Archives of Otorhinolaryngology, vol. 19, no. 3, pp. 191–195, 2015.

[6] W. M. Lydiatt, A. R. Shaha, and J. P. Shah, “Angiosarcoma of the head and neck,” The American Journal of Surgery, vol. 168, no. 5, pp. 451–454, 1994.

[7] R. J. Mark, J. C. Poen, L. M. Tran, Y. S. Fu, and G. F. Juillard, “Angiosarcoma. A report of 67 patients and a review of the literature,” Cancer, vol. 77, no. 11, pp. 2400–2406, 1996.

[8] P. P. Sordillo, R. Chapman, S. I. Hajdu, G. B. Magill, and R. B. Golbey, “Lymphangiosarcoma,” Cancer, vol. 48, no. 7, pp. 1674–1679, 1981.

[9] K. T. K. Chen, K. D. Hoffman, and E. J. Hendricks, “Angiosarcoma following therapeutic irradiation,” Cancer, vol. 44, no. 6, pp. 2044–2048, 1979.

[10] J. C. Maddox and H. L. Evans, “Angiosarcoma of skin and soft tissue: a study of forty-four cases,” Cancer, vol. 48, no. 8, pp. 1907–1921, 1981.

[11] T. M. Pawlik, A. F. Paulino, C. J. McGinn et al., “Cutaneous angiosarcoma of the scalp: a multidisciplinary approach,” Cancer, vol. 98, no. 8, pp. 1716–1726, 2003.

[12] D. J. Hodgkinson, E. H. Soule, and J. E. Woods, “Cutaneous angiosarcoma of the head and neck,” Cancer, vol. 44, no. 3, pp. 1106–1113, 1979.

[13] B. A. Guadagnolo, K. G. Zagars, D. Araujo, V. Ravi, T. D. Shellenberger, and E. M. Sturgis, “Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp,” Head & Neck, vol. 33, no. 5, pp. 661–667, 2011.

[14] S. H. Patel, R. E. Hayden, M. L. Hinini et al., “Angiosarcoma of the scalp and face: the Mayo Clinic experience,” JAMA Otolaryngology—Head & Neck Surgery, vol. 141, no. 4, pp. 335–340, 2013.

[15] S. Singla, P. Papavasililiou, B. Powers et al., “Challenges in the treatment of angiosarcoma: a single institution experience,” The American Journal of Surgery, vol. 208, no. 2, pp. 254–259, 2014.

[16] A. Buschmann, M. Lehnhardt, N. Toman, P. Preller, M. S. Salakdeh, and T. Muehlberger, “Surgical treatment of angiosarcoma of the scalp: less is more,” Annals of Plastic Surgery, vol. 61, no. 4, pp. 399–403, 2008.

[17] N. Naka, M. Ohsawa, Y. Tomita, H. Kanno, A. Uchida, and K. Aozasa, “Angiosarcoma in Japan.A review of 99 cases,” Cancer, vol. 75, no. 4, pp. 989–996, 1995.

[18] D. E. Tolhurst, M. H. Carstens, R. J. Greco, and D. J. Hurwitz, “The surgical anatomy of the scalp,” Plastic and Reconstructive Surgery, vol. 87, no. 4, pp. 603–614, 1991.

[19] W. H. Morrison, R. M. Byers, A. S. Garden, H. L. Evans, K. K. Ang, and L. J. Peters, “Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma,” Cancer, vol. 76, no. 2, pp. 319–327, 1995.

[20] T. Ohguri, H. Imada, S. Nomoto et al., “Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1446–1453, 2003.
[21] H. F. Köhler, R. I. Neves, E. R. Brechtbühl, N. V. Mattos Granja, M. K. Ikeda, and L. P. Kowalski, "Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution," Otolaryngology: Head and Neck Surgery, vol. 139, no. 4, pp. 519–524, 2008.

[22] S.-Y. Lim, J.-K. Pyon, G.-H. Mun, S.-I. Bang, and K.-S. Oh, "Surgical treatment of angiosarcoma of the scalp with superficial parotidectomy," Annals of Plastic Surgery, vol. 64, no. 2, pp. 180–182, 2010.

[23] K. Ogawa, K. Takahashi, Y. Asato et al., “Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients," The British Journal of Radiology, vol. 85, no. 1019, pp. e1127–e1133, 2012.

[24] T. Dettenborn, K. Wernker, H.-J. Schulze, M. Klein, V. Schwipper, and C. Hallermann, “Prognostic features in angiosarcoma of the head and neck: a retrospective monocenter study," Journal of Cranio-Maxillofacial Surgery, vol. 42, no. 8, pp. 1623–1628, 2014.

[25] R. Bullen, P. O. Larson, A. E. Landeck et al., "Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature," Dermatologic Surgery, vol. 24, no. 10, pp. 1105–1110, 1998.

[26] B. J. Kim, S. K. Park, and H. Chang, “The effectiveness of mapping biopsy in patients with extramammary Paget’s disease," Archives of Plastic Surgery, vol. 41, no. 6, pp. 753–758, 2014.

[27] M. G. Fury, C. R. Antonescu, K. J. Van Zee, M. F. Brennan, and R. G. Maki, "A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy," Cancer Journal, vol. 11, no. 3, pp. 241–247, 2005.

[28] R. Isogai, A. Kawada, Y. Aragane, and T. Tezuka, “Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel," The Journal of Dermatology, vol. 31, no. 4, pp. 335–341, 2004.

[29] K. M. Skubitz and P. A. Haddad, “Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma," Cancer, vol. 104, no. 2, pp. 361–366, 2005.

[30] U. Wollina, J. Füller, T. Graefe, M. Kaatz, and E. Lopatta, "Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy," Journal of Cancer Research and Clinical Oncology, vol. 127, no. 6, pp. 396–399, 2001.